{"id":"18f-rhpsma-7-3","safety":{"commonSideEffects":[{"rate":null,"effect":"Radiation exposure (inherent to PET imaging)"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This radiopharmaceutical is a positron emission tomography (PET) tracer composed of a recombinant human PSMA-targeting ligand labeled with the radioactive isotope fluorine-18. It localizes to PSMA-expressing cells, primarily in prostate cancer lesions, allowing clinicians to visualize and detect metastatic disease and guide treatment decisions.","oneSentence":"18F-rhPSMA-7.3 is a fluorine-18 labeled imaging agent that binds to prostate-specific membrane antigen (PSMA) on prostate cancer cells to enable PET imaging detection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:25:03.250Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"PET imaging of PSMA-positive lesions in men with prostate cancer"}]},"trialDetails":[{"nctId":"NCT05678322","phase":"PHASE3","title":"Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2023-01-31","conditions":"Prostate Cancer","enrollment":26},{"nctId":"NCT07011342","phase":"NA","title":"Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment","status":"RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2025-10-01","conditions":"Prostate Cancer","enrollment":70},{"nctId":"NCT07025369","phase":"PHASE2","title":"Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-08-25","conditions":"Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8","enrollment":30},{"nctId":"NCT07164027","phase":"EARLY_PHASE1","title":"Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2025-11-14","conditions":"Prostate Carcinoma","enrollment":30},{"nctId":"NCT05413850","phase":"PHASE1, PHASE2","title":"Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection","status":"RECRUITING","sponsor":"Blue Earth Therapeutics Ltd","startDate":"2022-07-20","conditions":"Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC","enrollment":82},{"nctId":"NCT07285057","phase":"PHASE2","title":"Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2026-02-10","conditions":"Prostatic Neoplasms, Prostate Cancer, Prostate Adenocarcinoma","enrollment":120},{"nctId":"NCT03995888","phase":"PHASE1","title":"Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer","status":"COMPLETED","sponsor":"Blue Earth Diagnostics","startDate":"2019-06-11","conditions":"Prostate Cancer","enrollment":24},{"nctId":"NCT06105918","phase":"PHASE1","title":"Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2023-11-29","conditions":"Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma","enrollment":6},{"nctId":"NCT07220720","phase":"PHASE2","title":"POSLUMA® (18F-rhPSMA-7.3) PET-CT for PIRADS 2/3 Lesions","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2025-11-04","conditions":"Prostate","enrollment":30},{"nctId":"NCT06479187","phase":"PHASE4","title":"PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2024-06-30","conditions":"Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer (mHSPC)","enrollment":20},{"nctId":"NCT05779943","phase":"PHASE2","title":"Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2023-04-27","conditions":"Prostate Adenocarcinoma, Recurrent Prostate Carcinoma","enrollment":20},{"nctId":"NCT06389786","phase":"NA","title":"Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-06-11","conditions":"Localized Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Stage I Prostate Cancer AJCC v8","enrollment":50},{"nctId":"NCT04186845","phase":"PHASE3","title":"Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence","status":"COMPLETED","sponsor":"Blue Earth Diagnostics","startDate":"2020-05-04","conditions":"Prostate Cancer","enrollment":391},{"nctId":"NCT06580015","phase":"NA","title":"[18F]-rhPSMA PET-CT Imaging Performance in Patients With Prostate Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-03-25","conditions":"Prostate Carcinoma","enrollment":20},{"nctId":"NCT06865768","phase":"PHASE2","title":"An Investigational Scan (18F-rhPSMA-7.3 PET-mpMRI) for Targeted Prostate Biopsy Using TRUS-MR Fusion Technique","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-04-18","conditions":"Prostate Carcinoma","enrollment":90},{"nctId":"NCT05852041","phase":"EARLY_PHASE1","title":"rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2023-06-07","conditions":"Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8","enrollment":40},{"nctId":"NCT04186819","phase":"PHASE3","title":"Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.","status":"COMPLETED","sponsor":"Blue Earth Diagnostics","startDate":"2020-03-02","conditions":"Prostate Cancer","enrollment":356},{"nctId":"NCT06813898","phase":"EARLY_PHASE1","title":"An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2025-02-17","conditions":"Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma","enrollment":27},{"nctId":"NCT06617481","phase":"PHASE2","title":"PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence","status":"RECRUITING","sponsor":"AdventHealth","startDate":"2024-09-20","conditions":"Prostate Cancer (Post Prostatectomy)","enrollment":30},{"nctId":"NCT04978675","phase":"PHASE1","title":"An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-08-04","conditions":"Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma, Prostate Adenocarcinoma","enrollment":29},{"nctId":"NCT05707182","phase":"EARLY_PHASE1","title":"18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: a Pilot Study","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2025-04-30","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT05799248","phase":"PHASE3","title":"Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management","status":"RECRUITING","sponsor":"MidLantic Urology","startDate":"2023-04-27","conditions":"Prostate Cancer","enrollment":113}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"18F-rhPSMA-7.3","genericName":"18F-rhPSMA-7.3","companyName":"Hackensack Meridian Health","companyId":"hackensack-meridian-health","modality":"Small molecule","firstApprovalDate":"","aiSummary":"18F-rhPSMA-7.3 is a fluorine-18 labeled imaging agent that binds to prostate-specific membrane antigen (PSMA) on prostate cancer cells to enable PET imaging detection. Used for PET imaging of PSMA-positive lesions in men with prostate cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}